Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Veklury | remdesivir | COVID-19 in non-hospitalized patients | Active | |||
TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended | |||
NA | icatibant | Hereditary Angioedema | Active | |||
Truqap | capivasertib | HR-positive, HER2-negative locally advanced or metastatic breast cancer | Active | |||
N/A | nab-paclitaxel | Gastrointestinal cancer | Pending | |||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | |||
Velsipity | etrasimod | Ulcerative colitis | Active | |||
Apretude | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
Dificid | fidaxomicin | Clostridium difficile infection | Active | |||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Active |